# OTC nasal spray seemed to cut COVID infections by 67% in mid-sized trial
- ğŸ“… æ¥æº: Ars Technica AI
- ğŸ•’ å‘å¸ƒæ—¶é—´ï¼ˆä¸œå…«åŒºï¼‰: 2025-09-03 06:36:26
- ğŸ”— [åŸæ–‡é“¾æ¥](https://arstechnica.com/health/2025/09/otc-nasal-spray-seemed-to-cut-covid-infections-by-67-in-mid-sized-trial/)

The Phase 2 trial is not definitive, but it comes as vaccine access is severely restricted.